Histopathologic Validation of 3′-Deoxy-3′-18F-Fluorothymidine PET in Squamous Cell Carcinoma of the Oral Cavity

被引:18
作者
Troost, Esther G. C. [1 ]
Bussink, Johan [1 ]
Slootweg, Piet J. [2 ]
Peeters, Wenny J. M. [1 ]
Merkx, Matthias A. W. [3 ]
van der Kogel, Albert J. [1 ]
Oyen, Wim J. G. [4 ]
Kaanders, Johannes H. A. M. [1 ]
机构
[1] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Radiat Oncol, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Pathol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Maxillofacial Surg, NL-6500 HB Nijmegen, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Inst Oncol, Dept Nucl Med, NL-6500 HB Nijmegen, Netherlands
关键词
F-18-fluorothymidine PET; proliferation; head and neck cancer; immunohistochemistry; iododeoxyuridine; thymidine kinase; CYTOSOLIC THYMIDINE KINASE; F-18-FLT PET; NECK-CANCER; IMAGING PROLIFERATION; NUCLEAR ANTIGEN; IN-VIVO; RADIOTHERAPY; HEAD; REPOPULATION; THERAPY;
D O I
10.2967/jnumed.109.071910
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Accelerated tumor cell repopulation is an important mechanism adversely affecting therapeutic outcome in head and neck cancer. The noninvasive assessment of the proliferative state of a tumor by PET may provide a selection tool for customized treatment. 3'-deoxy-3'-F-18-fluorothymidine (F-18-FLT) is a PET tracer that is phosphorylated by thymidine kinase 1 (TK-1) and, as such, reflects cellular proliferation. Before the use of F-18-FLT PET for tumor characterization is accepted and introduced into clinical studies, validation against tumor histology is mandatory. The aim of this study was to validate F-18-FLT PET in squamous cell carcinomas of the oral cavity using immunohistochemical staining for the proliferation marker iododeoxyuridine and for TK-1. Methods: Seventeen patients with primary squamous cell carcinomas of the oral cavity underwent an F-18-FLT PET/CT scan before surgery, and iododeoxyuridine was administered 20 min before tumor resection. F-18-FLT PET/CT scans were segmented, and PET/CT volumes and PET signal intensities were calculated (mean standardized uptake value [SUVmean] and maximum standardized uptake value [SUVmax]). Multiple paraffin-embedded tumor sections were immunohistochemically stained for iododeoxyuridine and TK-1. For iododeoxyuridine, labeling indices and optical densities were calculated and correlated with SUVmean and SUVmax. TK-1 staining was visually and semiquantitatively assessed. Results: All primary tumors were identified with F-18-FLT PET but with a large range in tracer uptake (mean SUVmax, 5.9; range, 2.2-15.2). Also, there was a large variability in iododeoxyuridine labeling indices (mean, 0.09; range, 0.01-0.29) and optical densities (mean, 28.2; range, 12.6-37.8). The iododeoxyuridine optical densities correlated significantly with SUVmean and SUVmax, but the labeling indices did not. In most tumors, TK-1 staining of varying intensity was present but correlated with neither iododeoxyuridine binding nor F-18-FLT uptake. Conclusion: The current study demonstrated only a weak correlation between F-18-FLT uptake and iododeoxyuridine staining intensity in oral cavity tumors. This weak correlation may be explained by differences in biomarker characteristics, resolution, and quantification methods.
引用
收藏
页码:713 / 719
页数:7
相关论文
共 50 条
  • [21] In vivo imaging of cell proliferation in meningioma using 3′-deoxy-3′-[18F]fluorothymidine PET/MRI
    Bashir, Asma
    Binderup, Tina
    Vestergaard, Mark Bitsch
    Broholm, Helle
    Marner, Lisbeth
    Ziebell, Morten
    Fugleholm, Kare
    Kjaer, Andreas
    Law, Ian
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (06) : 1496 - 1509
  • [22] Fast and efficient microscale radiosynthesis of 3′-deoxy-3′-[18F]fluorothymidine
    Koag, Myong Chul
    Kim, Hee-Kwon
    Kim, Andrew Sungjoon
    JOURNAL OF FLUORINE CHEMISTRY, 2014, 166 : 104 - 109
  • [23] Efficient Radiosynthesis of 3′-Deoxy-3′-18F-Fluorothymidine Using Electrowetting-on-Dielectric Digital Microfluidic Chip
    Javed, Muhammad Rashed
    Chen, Supin
    Kim, Hee-Kwon
    Wei, Liu
    Czernin, Johannes
    Kim, Chang-Jin CJ
    Dam, R. Michael van
    Keng, Pei Yuin
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (02) : 321 - 328
  • [24] Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non-Small Cell Lung Cancer Using 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET
    Kahraman, Deniz
    Scheffler, Matthias
    Zander, Thomas
    Nogova, Lucia
    Lammertsma, Adriaan A.
    Boellaard, Ronald
    Neumaier, Bernd
    Ullrich, Roland T.
    Holstein, Arne
    Dietlein, Markus
    Wolf, Juergen
    Kobe, Carsten
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (12) : 1871 - 1877
  • [25] Differential 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Responses to Pharmacologic Inhibition of the c-MET Receptor in Preclinical Tumor Models
    Cullinane, Carleen
    Dorow, Donna S.
    Jackson, Susan
    Solomon, Benjamin
    Bogatyreva, Ekaterina
    Binns, David
    Young, Richard
    Arango, Maria E.
    Christensen, James G.
    McArthur, Grant A.
    Hicks, Rodney J.
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (08) : 1261 - 1267
  • [26] PET/CT with 3′-deoxy-3′-[18F]fluorothymidine for lung cancer patients receiving carbon-ion radiotherapy
    Saga, Tsuneo
    Koizumi, Mitsuru
    Inubushi, Masayuki
    Yoshikawa, Kyosan
    Tanimoto, Katsuyuki
    Fukumura, Toshimitsu
    Miyamoto, Tadaaki
    Nakajima, Mio
    Yamamoto, Naoyoshi
    Baba, Masayuki
    NUCLEAR MEDICINE COMMUNICATIONS, 2011, 32 (05) : 348 - 355
  • [27] 3′-Deoxy-3′-18F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer
    Challapalli, Amarnath
    Barwick, Tara
    Pearson, Rachel A.
    Merchant, Shairoz
    Mauri, Francesco
    Howell, Elizabeth C.
    Sumpter, Katherine
    Maxwell, Ross J.
    Aboagye, Eric O.
    Sharma, Rohini
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (06) : 831 - 840
  • [28] 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography for response assessment in soft tissue sarcoma
    Benz, Matthias R.
    Czernin, Johannes
    Allen-Auerbach, Martin S.
    Dry, Sarah M.
    Sutthiruangwong, Piriya
    Spick, Claudio
    Radu, Caius
    Weber, Wolfgang A.
    Tap, William D.
    Eilber, Fritz C.
    CANCER, 2012, 118 (12) : 3135 - 3144
  • [29] Thymidine Metabolism as a Confounding Factor for 3'-Deoxy-3'-18F-Fluorothymidine Uptake After Therapy in a Colorectal Cancer Model
    Schelhaas, Sonja
    Wachsmuth, Lydia
    Hermann, Sven
    Rieder, Natascha
    Heller, Astrid
    Heinzmann, Kathrin
    Honess, Davina J.
    Smith, Donna-Michelle
    Fricke, Inga B.
    Just, Nathalie
    Doblas, Sabrina
    Sinkus, Ralph
    Doering, Christian
    Schaefers, Klaus P.
    Griffiths, John R.
    Faber, Cornelius
    Schneider, Richard
    Aboagye, Eric O.
    Jacobs, Andreas H.
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (07) : 1063 - 1069
  • [30] USE OF 3'-DEOXY-3'-[18F]FLUOROTHYMIDINE PET/CT FOR EVALUATING RESPONSE TO CYTOTOXIC CHEMOTHERAPY IN DOGS WITH NON-HODGKIN'S LYMPHOMA
    Lawrence, Jessica
    Vanderhoek, Matthew
    Barbee, David
    Jeraj, Robert
    Tumas, Daniel B.
    Vail, David M.
    VETERINARY RADIOLOGY & ULTRASOUND, 2009, 50 (06) : 660 - 668